SCHEMBL7011360

SCHEMBL7011360

N#CN1CCCC1CNS(=O)(=O)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTSK P43235 7/20 1.00
CTSL P07711 5/20 1.00
CTSB P07858 6/20 0.62
GBA1 P04062 1/20 0.52
ALDH1A1 P00352 2/20 0.51
PKM P14618 2/20 0.51
UCHL1 P09936 5/20 0.49
USP30 Q70CQ3 5/20 0.49
CTSS P25774 2/20 0.49
CTSC P53634 2/20 0.49
DPP4 P27487 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.47
DPP8 Q6V1X1 2/20 0.46
DPP9 Q86TI2 2/20 0.46
DPP7 Q9UHL4 2/20 0.46
LOX P28300 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6859830 0.81 CTSL (0.67) CTSKCTSLCTSBALDH1A1USP30
SCHEMBL5250912 0.77 ATM (0.75) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL6856492 0.76 CTSK (1.00) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL6858391 0.75 CTSK (1.00) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL18422980 0.74 CTSL (0.58) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL6856184 0.74 CTSL (1.00) CTSKCTSLCTSBUSP30DPP4
SCHEMBL3811045 0.70 GBA1 (0.86) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL8394068 0.70 GBA1 (0.86) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL25202837 0.70 ALDH1A1 (0.65) CTSKCTSLCTSBGBA1ALDH1A1
SCHEMBL14532259 0.70 GBA1 (0.58) CTSKCTSLCTSBGBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272467-A4 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2003-05-07 EP claimed
EP-1272467-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2003-01-08 EP claimed
WO-2001077073-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-10-18 WO claimed
US-6835727-B2 Bone disorders; osteoporosis; rheumatic diseases MERCK FROSST CANADA & CO. (CA) 2004-12-28 US disclosed
US-20030229226-A1 Cathepsin cysteine protease inhibitors MERCK FROSST CANADA LTD. (CA) 2003-12-11 US disclosed
EP-1272467-A4 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2003-05-07 EP disclosed
EP-1272467-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2003-01-08 EP disclosed
WO-2001077073-A1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229226-A1 Cathepsin cysteine protease inhibitors CTSK, CTSZ, CTSE CTSK 1/4885CTSL 10/4885CTSB 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.